ImpACt of Very High Protein Content Enteral nUtrition Formulas on Critically Ill MUltipLe trAuma paTiEnts (ACCUMULATE)

ImpACt of Very High Protein Content Enteral nUtrition Formulas on Protein Metabolism and Residual Gastric Volume in Critically Ill MUltipLe trAuma paTiEnts

This prospective observational randomized study aims to determine energy, protein intake and gastrointestinal tolerance while using enteral nutrition formulas with very high protein content and enteral nutrition formulas with normal protein content.

• Differences regarding achieving protein and calorie daily targets when using enteral nutrition formulas with different protein content
• Differences regarding residual gastric volume when using enteral nutrition formulas with different protein content
• Differences regarding body composition when using enteral nutrition formulas with different protein content

Study Overview

• Status: Recruiting
• Conditions: Trauma; Gastroparesis; Muscle Loss; Metabolism; Nutritional Deficiency; Protein Malnutrition; Calorie Malnutrition Protein
• Intervention / Treatment: Other: Medical food

Detailed Description

ImpACt of very high protein Content enteral nUtrition formulas on protein metabolism and residual gastric volume in critically ill MUltipLe trAuma paTiEnts

- ACCUMULATE trial -

Background and rationale:

Despite an increased survival among critically ill patients, many of the ICU "survivors" may develop prolonged functional disabilities. It has already been proven that nutritional therapy is essential, considering that an adequate provision of calories and proteins may influence patients prognostic.

Multiple trauma patients are on a particular nutritional risk, since their high nitrogen demands and associated nutritional therapy challenges, caused by repeated surgical intervention or multiple imagistic procedures. Although nutritional therapy impact on mortality is still in debate, clear, positive results were obtained in decreasing ICU and hospital stay after adequate nutritional support.

According to ESPEN guideline on clinical nutrition in the ICU early enteral nutrition (within 48 h) should be initiated in order to assure an adequate calorie and protein intake. Beside optimal timing, the management of nutrition therapy in critically ill patients should also integrate the optimal route and caloric/protein targets.

Energy requirements monitoring through indirect calorimetry has been proposed as a standard-of-care method for critically ill patients, considering its proven superiority towards predictive equation.

Beyond calorie intake, proteins proved to play a central role in maintain lean body mass, healing wounds and supporting immune function.For multiple trauma patients it was reported that protein losses may reach 14 % of the total body stores, thus this type of patients are exposed to a particular increased risk of protein deficits. If calorie administration benefits from a proper monitoring tool, protein requirements are still based on predictive equation. The impact of protein administration is also lacking of direct measurements techniques. Lean body mass evaluation by ultrasound and computerized tomography has been reported to have a good correlation with hospital stay and pots-ICU functional capacity. Moreover muscle function evaluation through a hand-grip dynamometer was also tested with good results in patients with ARDS.

Source of administered protein may also influence nitrogen balance, considering that whey proteins (rich in leucine) promote a slower hydrolysis and allow a longer period for absorption.

Reaching the recommended goals is often impeded by gastric intolerance manifested through increased gastric volume residues. It has been already demonstrated that large gastric volume residues are associated with impaired absorption and an increased incidence of aspiration pneumonia.

Gastrointestinal dysfunction in multiple trauma patients admitted to the intensive care unit (ICU) is an important yet underrecognized consequence. There are various causes of gastrointestinal tract dysfunction mostly related to patients general health condition and to their diagnostics. Gastrointestinal failure may be induced by several factors like immunological, biological and mechanical barrier disruption and it may be manifested through stress ulceration, bacterial translocation, ileus, intra-abdominal hypertension, diarrhoea and constipation.

Whether residual gastric volume monitoring should be regularly performed has been extensively discussed. Although the results from some randomised trials which focused on monitoring gastric residual volume, did not find any difference in outcomes, this measurement was far for being abandoned. Moreover, gastric residual volume monitoring is still an essential component of enteral nutrition patient care.

Although several monitoring methods for gastric volume residue measurements were described, there is no generally accepted technique for daily use.

Objective:

This prospective observational randomized study aims to determine energy, protein intake and gastrointestinal tolerance while using enteral nutrition formulas with very high protein content and enteral nutrition formulas with normal protein content.

Safety points:

• Clinical parameters - vomiting, diarrhoea
• Biochemical parameters - base excess, urea levels
• Daily gastric residual volume evaluation using ultrasound gastric antrum measurements after 24 hours of continuous enteral nutrition administration using both types of formulas;

Study population Consecutive patients with multiple trauma intubated and mechanical ventilated, admitted to the intensive care unit (ICU).

Sample size calculation Since the hypotheses of the study are exploratory, no formal sample size calculation has been performed. This prospective observational study aims to recruit>70 multiple trauma patients.

Randomization:

Simple randomization method will be used to assign subjects into two groups A and B.

Ethical considerations:

This study will be conducted in full conformity with the Declaration of Helsinki and Good Clinical Practices.

Local ethical committee approval will be asked before any patient will be included.

Considering that nutritional support has become a standard-of-care in every intensive care unit in the world, it is considered that this research is based on collecting data routinely available for every critically ill patient. Although no intervention is performed an informed consent will be provided.

Taking into account that the included patients are not able to provide informed consent at the time of recruitment (on ICU admission), a Power of Attorney or a Legal tutor will act as Consultee and will be asked to consent/decline participation to the study on legal behalf of the patient. If patients have Advance Decision Plan including participation in research studies the Plan will be respected and recruitment pursued/abandoned accordingly.

After regaining capacity, all patients will be asked to provide Informed Consent for using their personal data and will be given the possibility to:

Provide Informed Consent for the acute data and follow-up. Deny research participation and request destruction of acute data collected.

Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to the Data Manager and the Statistician of the study.

Expected impact of the study KNOWLEDGE The investigators aim to provide a detailed description of protein administration using two different types of enteral formulas. The main objectives of the study are to evaluate energy, protein intake and gastrointestinal tolerance while using enteral nutrition formulas with different protein content. Nevertheless, the investigators want to provide data about the impact of these different enteral nutrition formulas on body composition as well as on functionality.

Regarding of the obtained data a change on local and national recommendation considering enteral nutrition in multiple trauma patients is to be expected.

Funding All the enteral nutrition products are donated by the Nutricia Global. No funding will be received for this study.

• Study Type: Observational
• Enrollment (Estimated): 70

Contacts and Locations

• Study Contact: Name: Ioana Grintescu, MD, PhD; Phone Number: +40722329187; Email: ioana.grintescu@rospen.ro
• Study Contact Backup: Name: Cristian Cobilinschi, MD, PhD; Phone Number: +40765018776; Email: cristian.cobilinschi@umfcd.ro

Study Locations

• Romania
  • Bucharest, Romania
    • Recruiting
    • Clinical Emergency Hospital of Bucharest
    • Contact: Cristian Cobilinschi, MD, PhD; Phone Number: +40765018776; Email: cristian.cobilinschi@umfcd.ro
    • Contact: Ioana Grințescu, Professor; Phone Number: +40722329187; Email: ioana.grintescu@rospen.ro
    • Principal Investigator: Liliana Mirea, MD, PhD
    • Principal Investigator: Raluca Ungureanu, MD, PhD
    • Principal Investigator: Cristian Cobilinschi, MD, PhD
    • Principal Investigator: Ioana Grintescu, MD, PhD
    • Principal Investigator: Ana Maria Cotae, MD
    • Sub-Investigator: Diana Iacob, MD
    • Sub-Investigator: Angela Popa, MD
    • Sub-Investigator: Ioana Dumitru, MD
    • Sub-Investigator: Mihaela Buiuc, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

Consecutive patients with multiple trauma intubated and mechanical ventilated, admitted to the intensive care unit (ICU)

Description

Inclusion Criteria:

• Adult patients (>18 yrs) admitted to the ICU
• Multiple trauma (Injury severity score > 18)
• Intubation and mechanical ventilation upon admission in ICU or during the first 24 hours of admission, for at least 48 h

Exclusion Criteria:

• Age < 18 years
• Pregnant women
• Patients not intubated or not mechanically ventilated or receiving only non-invasive ventilation
• Patients with enteral feeding contraindication 48 h after admission
• Patients with recent gastrointestinal surgical intervention
• Patients on chronic therapy with corticosteroids

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Group A; Group A - enteral formula with 6.3 g/100 ml protein	Other: Medical food; enteral formulas with different protein composition
Group B; enteral formula with 10 g/100 ml protein	Other: Medical food; enteral formulas with different protein composition

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Calorie and protein target	Differences regarding achieving protein and calorie daily targets in grams per kilogram of body weight (g/kg BW) at day 5 of the intervention period and at day 10 when using enteral nutrition formulas with different protein content	on day 5 days
Calorie and protein target	Differences regarding achieving protein and calorie daily targets in grams per kilogram of body weight (g/kg BW) at day 5 of the intervention period and at day 10 when using enteral nutrition formulas with different protein content	on day 10

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ultrasound-guided assessment of gastric residual volume	Differences regarding residual gastric volume when using enteral nutrition formulas with different protein content. Ultrasound assessment of gastric volume using a current model for GV assessment based on antral cross-sectional area (CSA) - GV (ml)1⁄427.0+14.6×right-lateral CSA (cm2)21.28×age (yr)	on day 5
Ultrasound-guided assessment of gastric residual volume	Differences regarding residual gastric volume when using enteral nutrition formulas with different protein content. Ultrasound assessment of gastric volume using a current model for GV assessment based on antral cross-sectional area (CSA) - GV (ml)1⁄427.0+14.6×right-lateral CSA (cm2)21.28×age (yr)	on day 10
Muscle function	Muscle function evaluation using handgrip dynamometer after extubation and sedation cessation	24 hours after extubation
Muscle function	Muscle function evaluation using handgrip dynamometer after extubation and sedation cessation	5 days after extubation
Body composition - Fat-free body mass	Fat-free body mass assessment using bioelectrical impedance analysis	24 hours after extubation
Body composition - Fat-free body mass	Fat-free body mass assessment using whole-body bioelectrical impedance	5 days after extubation
Body composition - Total body water	Total body water assessment using whole-body bioelectrical impedance analysis	24 hours after extubation
Body composition - Total body water	Total body water assessment using whole-body bioelectrical impedance analysis	5 days after extubation
Body composition - Phase angle	Phase angle measurement using whole-body bioelectrical impedance analysis	24 hours after extubation
Body composition - Phase angle	Phase angle measurement using whole-body bioelectrical impedance analysis	5 days after extubation
Body composition - ultrasound	Quadriceps rectus femoris thickness thickness measured by B-mode ultrasonography	baseline (on admission/first 24 hours)
Body composition - ultrasound	Quadriceps rectus femoris thickness measured by B-mode ultrasonography	on day 5
Body composition - ultrasound	Quadriceps rectus femoris thickness measured by B-mode ultrasonography	on day 10
Body composition - ultrasound	Quadriceps rectus femoris thickness measured by B-mode ultrasonography	on day 15
Inflammation - CRP	Plasmatic levels of C-reactive protein	on day 5
Inflammation - CRP	Plasmatic levels of C-reactive protein	on day 10
Inflammation - prealbumin	Plasmatic levels of prealbumin	on day 5
Inflammation - prealbumin	Plasmatic levels of prealbumin	on day 10

Collaborators and Investigators

• Sponsor: Romanian Society for Enteral and Parenteral Nutrition
• Investigators: Study Director: Ioana Grintescu, MD, PhD, Romanian Society of Enteral and Parenteral Nutrition

Publications and helpful links

General Publications

• van Zanten ARH, Petit L, De Waele J, Kieft H, de Wilde J, van Horssen P, Klebach M, Hofman Z. Very high intact-protein formula successfully provides protein intake according to nutritional recommendations in overweight critically ill patients: a double-blind randomized trial. Crit Care. 2018 Jun 12;22(1):156. doi: 10.1186/s13054-018-2070-5.
• Singer P. Protein metabolism and requirements in the ICU. Clin Nutr ESPEN. 2020 Aug;38:3-8. doi: 10.1016/j.clnesp.2020.03.026. Epub 2020 May 31.
• Tedeschi-Jockers F, Reinhold S, Hollinger A, Tuchscherer D, Kiss C, Gantner L, Ledergerber K, Zimmermann S, Scheuzger J, Huber J, Siegemund M. A new high protein-to-energy enteral formula with a whey protein hydrolysate to achieve protein targets in critically ill patients: a prospective observational tolerability study. Eur J Clin Nutr. 2022 Mar;76(3):419-427. doi: 10.1038/s41430-021-00956-9. Epub 2021 Jun 24.
• Berger MM, Reintam-Blaser A, Calder PC, Casaer M, Hiesmayr MJ, Mayer K, Montejo JC, Pichard C, Preiser JC, van Zanten ARH, Bischoff SC, Singer P. Monitoring nutrition in the ICU. Clin Nutr. 2019 Apr;38(2):584-593. doi: 10.1016/j.clnu.2018.07.009. Epub 2018 Jul 20.
• Yasuda H, Kondo N, Yamamoto R, Asami S, Abe T, Tsujimoto H, Tsujimoto Y, Kataoka Y. Monitoring of gastric residual volume during enteral nutrition. Cochrane Database Syst Rev. 2021 Sep 27;9(9):CD013335. doi: 10.1002/14651858.CD013335.pub2.

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2023
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): December 1, 2024

Study Registration Dates

• First Submitted: November 1, 2022
• First Submitted That Met QC Criteria: December 2, 2022
• First Posted (Actual): December 12, 2022

Study Record Updates

• Last Update Posted (Actual): July 22, 2024
• Last Update Submitted That Met QC Criteria: July 17, 2024
• Last Verified: July 1, 2024

More Information

Terms related to this study

• Keywords: body composition; enteral nutrition; multiple trauma; energy target; protein target; gastric residual volume; enteral nutrition intolerance
• Additional Relevant MeSH Terms: Digestive System Diseases; Neurologic Manifestations; Gastrointestinal Diseases; Stomach Diseases; Nutrition Disorders; Deficiency Diseases; Paralysis; Protein Deficiency; Severe Acute Malnutrition; Wounds and Injuries; Malnutrition; Multiple Trauma; Gastroparesis; Protein-Energy Malnutrition; Kwashiorkor
• Other Study ID Numbers: rospen9accumulate

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Data requests can be submitted by researchers in the field of clinical nutrition starting 9 months after article publication and the data will be made accessible for up to 3 years. Extensions will be considered on a case-by-case basis
• IPD Sharing Time Frame: 2024 3 years
• IPD Sharing Access Criteria: Interest in data analysis, appropriate background in the field
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No